Peptides
The next-generation molecules — retatrutide, survodutide, BPC-157, and the names you will hear by 2027.
The peptides desk is where the pipeline lives. We cover the molecules in late-stage trials, the research-grade peptide grey market, the compounding legal distinctions, and the ones every reader should be able to name by 2027.
This Week's Feature
BPC-157 Is Everywhere and Almost Nowhere in the Literature
The internet's favorite "healing peptide" has a robust mechanism story and almost zero human trial data. We went looking for what the published evidence actually supports — and what it does not.
Read the feature → Peptides Sermorelin Is the Quiet Comeback Story of Growth Hormone
A 1990s growth-hormone-releasing peptide is having a second life in longevity clinics. The mechanism is real. The clinical case is mixed. The market does not seem to care.
Peptides The Next Wave of Weight-Loss Peptides Is Already in Trials
Retatrutide, amylin agonists, orforglipron. The incretin pipeline has five drugs readers should know about, and the reason to care is that the clinical profile is meaningfully different from semaglutide and tirzepatide.